- Home
- MEIP vs PSHG Comparison
MEIP vs PSHG Comparison
Compare MEIP & PSHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- PSHG
- Stock Information
- Founded
- MEIP 2000
- PSHG 2010
- Country
- MEIP United States
- PSHG Greece
- Employees
- MEIP N/A
- PSHG N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- PSHG Marine Transportation
- Sector
- MEIP Health Care
- PSHG Consumer Discretionary
- Exchange
- MEIP Nasdaq
- PSHG Nasdaq
- Market Cap
- MEIP 17.1M
- PSHG 20.1M
- IPO Year
- MEIP 2003
- PSHG N/A
- Fundamental
- Price
- MEIP $2.15
- PSHG $1.57
- Analyst Decision
- MEIP Hold
- PSHG Strong Buy
- Analyst Count
- MEIP 2
- PSHG 1
- Target Price
- MEIP $7.00
- PSHG $6.50
- AVG Volume (30 Days)
- MEIP 8.3K
- PSHG 33.7K
- Earning Date
- MEIP 05-08-2025
- PSHG 02-20-2025
- Dividend Yield
- MEIP N/A
- PSHG N/A
- EPS Growth
- MEIP N/A
- PSHG N/A
- EPS
- MEIP N/A
- PSHG 1.11
- Revenue
- MEIP N/A
- PSHG $87,445,000.00
- Revenue This Year
- MEIP N/A
- PSHG N/A
- Revenue Next Year
- MEIP N/A
- PSHG $32.01
- P/E Ratio
- MEIP N/A
- PSHG $1.44
- Revenue Growth
- MEIP 33.76
- PSHG N/A
- 52 Week Low
- MEIP $2.15
- PSHG $1.48
- 52 Week High
- MEIP $4.11
- PSHG $2.58
- Technical
- Relative Strength Index (RSI)
- MEIP 27.69
- PSHG 47.37
- Support Level
- MEIP $2.28
- PSHG $1.53
- Resistance Level
- MEIP $2.35
- PSHG $1.68
- Average True Range (ATR)
- MEIP 0.07
- PSHG 0.05
- MACD
- MEIP -0.00
- PSHG 0.01
- Stochastic Oscillator
- MEIP 0.00
- PSHG 37.37
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.